Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Hematology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TIM-3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TIM-3 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View TIM-3 Products |
| Gene Delivery | TIM-3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View TIM-3 Products |
| Benchmark Ab | Anti-TIM-3 (Sequence of Sabatolimab/Cobolimab) Recombinant positive control. |
View TIM-3 Products |
| Validator | TIM-3 siRNA Set For knockdown verification. |
View TIM-3 Products |
| Related Target A | PD-1 (PDCD1) Synergistic immune checkpoint for bispecifics and combo therapies. |
View PDCD1 Products |
| Related Target B | LAG-3 Parallel exhaustion marker for combinatorial blockade. |
View LAG3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity |
| Ligand Binding Blockade (Galectin-9, CEACAM1) | Native glycosylation maintained via HEK293 expression systems |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives in Flow Cytometry | Validated siRNA included for specificity checks |
Live TIM-3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TIM-3 (HAVCR2) therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies (e.g., PD-1 x TIM-3). As first-generation therapies reach the clinic, primarily targeting myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), the next wave of R&D is targeting solid tumor microenvironments to overcome PD-1/PD-L1 resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Novartis, GSK | MDS, AML | Epitope Mapping (Need high-purity ECD-Fc) |
| Bispecific Antibody | Roche, Eli Lilly | Solid Tumors | Heterodimer Validation (Need Cross-reactive Abs) |
| Combination Therapy | Various | Refractory Cancers | Ligand Blockade Assay (Need Galectin-9 / CEACAM1 proteins) |